0000950103-23-013705.txt : 20230918 0000950103-23-013705.hdr.sgml : 20230918 20230918173022 ACCESSION NUMBER: 0000950103-23-013705 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230918 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230918 DATE AS OF CHANGE: 20230918 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Bausch Health Companies Inc. CENTRAL INDEX KEY: 0000885590 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-14956 FILM NUMBER: 231261964 BUSINESS ADDRESS: STREET 1: 2150 ST. ELZEAR BLVD. WEST STREET 2: LAVAL CITY: QUEBEC STATE: A8 ZIP: H7L 4A8 BUSINESS PHONE: 514-744-6792 MAIL ADDRESS: STREET 1: 2150 ST. ELZEAR BLVD. WEST STREET 2: LAVAL CITY: QUEBEC STATE: A8 ZIP: H7L 4A8 FORMER COMPANY: FORMER CONFORMED NAME: Valeant Pharmaceuticals International, Inc. DATE OF NAME CHANGE: 20100928 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL Corp DATE OF NAME CHANGE: 20100416 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL CORP INTERNATIONAL DATE OF NAME CHANGE: 19960522 8-K 1 dp200201_8k.htm FORM 8-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of the earliest event reported): September 18, 2023

Bausch Health Companies Inc.

(Exact Name of Registrant as Specified in Its Charter)

British Columbia, Canada

001-14956

98-0448205

(State or Other Jurisdiction of

Incorporation or Organization)

(Commission

File Number)

(I.R.S. Employer

Identification Number)

2150 St. Elzéar Blvd. West

Laval, Quebec

Canada H7L 4A8

(Address of Principal Executive Offices) (Zip Code)

514-744-6792

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Shares, No Par Value

BHC

New York Stock Exchange, Toronto Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 18, 2023, Tom Vadaketh informed Bausch Health Companies Inc. (the “Company”) of his decision to resign as the Executive Vice President, Chief Financial Officer of the Company. Mr. Vadaketh will depart the Company effective October 13, 2023 to pursue another opportunity. During his remaining period of employment, Mr. Vadaketh will continue to serve as the Company’s Chief Financial Officer, in order to support a seamless transition.

Mr. Vadaketh’s resignation was not because of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices, including accounting principles, practices and disclosures.

The Company has initiated a search for a permanent Chief Financial Officer. If a permanent replacement is not in place at the time that Mr. Vadaketh ceases to be the Chief Financial Officer, then, effective at such time, John S. Barresi, who is currently serving as the Company’s Senior Vice President, Controller and Chief Accounting Officer, will assume the additional role of interim Chief Financial Officer. Mr. Barresi has more than 15 years of experience as a corporate finance executive.

Mr. Barresi’s biographical information is set forth in the Company’s Form 8-K filed with the SEC on May 31, 2022, and such information is incorporated herein by reference. No family relationships exist between Mr. Barresi and any of the Company’s directors or other executive officers. There are no other arrangements between Mr. Barresi and any other person pursuant to which Mr. Barresi was selected as an officer, nor are there any transactions to which the Company is or was a participant and in which Mr. Barresi has a material interest subject to disclosure under Item 404(a) of Regulation S-K.

Item 7.01. Regulation FD Disclosure.

On September 18, 2023, the Company issued a press release announcing the resignation of Mr. Vadaketh. A copy of the press release is being furnished as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 7.01 of this Current Report on Form 8-K is being “furnished” and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or the Exchange Act, and shall not be incorporated or deemed to be incorporated by reference into any filing by the Company under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language contained in such filing, unless otherwise expressly stated in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit

Number	Exhibit Title or Description
99.1	Press Release by Bausch Health Companies Inc., dated September 18, 2023
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

Cautionary Statement Regarding Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, “forward-looking statements”) including, but not limited to, statements relating to the Company’s succession plan for its chief financial officer position. Forward-looking statements may generally be identified by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “will,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions, and phrases or statements that certain actions, events or results may, could, should or will be achieved, received or taken, or will occur or result, and similar such expressions also identify forward-looking information. These forward-looking statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in the Company’s filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Additional information regarding certain of these material factors and assumptions may be found in the Company’s filings described above. The Company believes that the material factors and assumptions reflected in these forward-looking statements are reasonable in the circumstances, but readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this Current Report on Form 8-K or to reflect actual outcomes, unless required by law. Readers are cautioned not to place undue reliance on any of these forward-looking statements.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BAUSCH HEALTH COMPANIES INC.

	By:	/s/ Seana Carson
	Name:	Seana Carson
	Title:	Executive Vice President, General Counsel

Date: September 18, 2023

EX-99.1 2 dp200201_ex9901.htm EXHIBIT 99.1

Exhibit 99.1

Investor Contacts:	Media Contact:
John O’Connor	Kevin Wiggins
ir@bauschhealth.com	corporate.communications@bauschhealth.com
(908) 541-2973	(908) 927-1198

Mark Maico
ir@bauschhealth.com
(908) 541-2102
(877) 281-6642 (toll free)

BAUSCH HEALTH ANNOUNCES CFO TRANSITION PLAN

LAVAL, Quebec, Sept. 18, 2023 - Bausch Health Companies Inc. (NYSE/TSX: BHC) (“BHC” or the “Company”) today announced that Tom Vadaketh, Executive Vice President, Chief Financial Officer, has resigned from his role to pursue another opportunity, and will be leaving the Company effective October 13, 2023. The Company thanks Mr. Vadaketh for his significant contributions and leadership during a period of transition at the Company.

A formal search process to identify Mr. Vadaketh’s permanent replacement has been initiated.

If a permanent replacement is not in place at the time of Mr. Vadaketh’s departure, the Company intends to appoint John S. Barresi, who is currently serving as the Company’s Senior Vice President, Controller and Chief Accounting Officer, to the role of interim Chief Financial Officer. Mr. Barresi has more than 15 years of experience as a corporate finance executive.

About Bausch Health

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global diversified pharmaceutical company whose mission is to improve people’s lives with our healthcare products. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our controlling ownership interest in Bausch + Lomb Corporation. With our leading durable brands, we are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn.

Forward-looking Statements

This news release contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, “forward-looking statements”), including, but not limited to, statements relating to the Company’s succession plan for its chief financial officer position. Forward-looking statements may generally be identified by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions, and phrases or statements that certain actions, events or results may, could, should or will be achieved, received or taken, or will occur or result, and similar such expressions also identify forward-looking information. These forward-looking statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in the Company’s most recent annual and quarterly reports and detailed from time to time in the Company’s other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which risks and uncertainties are incorporated herein by reference. Additional information regarding certain of these material factors and assumptions may be found in the Company’s filings described above. The Company believes that the material factors and assumptions reflected in these forward-looking statements are reasonable in the circumstances, but readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

EX-101.SCH 3 bhc-20230918.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 bhc-20230918_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 bhc-20230918_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT

Cover	Sep. 18, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Sep. 18, 2023
Entity File Number	001-14956
Entity Registrant Name	Bausch Health Companies Inc.
Entity Central Index Key	0000885590
Entity Tax Identification Number	98-0448205
Entity Incorporation, State or Country Code	A1
Entity Address, Address Line One	2150 St. Elzéar Blvd. West
Entity Address, City or Town	Laval
Entity Address, State or Province	QC
Entity Address, Country	CA
Entity Address, Postal Zip Code	H7L 4A8
City Area Code	514
Local Phone Number	744-6792
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Shares, No Par Value
Trading Symbol	BHC
Security Exchange Name	NYSE
Entity Emerging Growth Company	false

XML 7 dp200201_8k_htm.xml IDEA: XBRL DOCUMENT 0000885590 2023-09-18 2023-09-18 iso4217:USD shares iso4217:USD shares 0000885590 false A1 8-K 2023-09-18 Bausch Health Companies Inc. 001-14956 98-0448205 2150 St. Elzéar Blvd. West Laval QC CA H7L 4A8 514 744-6792 false false false false Common Shares, No Par Value BHC NYSE false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://bauschhealth.com/role/Cover Cover Cover 1 false false All Reports Book All Reports bhc-20230918.xsd bhc-20230918_lab.xml bhc-20230918_pre.xml dp200201_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "dp200201_8k.htm": { "nsprefix": "BHC", "nsuri": "http://bauschhealth.com/20230918", "dts": { "schema": { "local": [ "bhc-20230918.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "bhc-20230918_lab.xml" ] }, "presentationLink": { "local": [ "bhc-20230918_pre.xml" ] }, "inline": { "local": [ "dp200201_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://bauschhealth.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-09-18", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "dp200201_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-18", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "dp200201_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://bauschhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0000950103-23-013705-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950103-23-013705-xbrl.zip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end